CompletedInterventionalPhase 2Last updated Nov 15, 2013

Study Evaluating Bapineuzumab In Alzheimer Disease Subjects

A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Multiple Ascending Dose Safety, Tolerability, Reactogenicity, And Pharmacokinetic Study Of Bapineuzumab (AAB 001) Administered Subcutaneously In Subjects With Mild To Moderate AD

Overview

ClinicalTrials.gov ID: NCT00663026
Lead Sponsor: PfizerINDUSTRY
Brief Summary: The study will evaluate the safety and effectiveness of bapineuzumab for the treatment of mild to moderate Alzheimer disease. Subjects will be in the study for six months and will receive subcutaneous injections once per week.
Study Type: Interventional

Status

Overall Status: Completed
Start Date: Nov 2008
Primary Completion Date: Oct 2010Actual
Completion Date: Oct 2010Actual

Study Record Dates

First Submitted: Apr 17, 2008
First Submitted that Met QC Criteria: Apr 19, 2008
First Posted: Apr 21, 2008Estimated
Last Update Submitted that Met QC Criteria: Sep 11, 2013
Last Update Posted: Nov 15, 2013Estimated
Last Verified: Sep 2013

NCT00676143Terminated

Study Evaluating the Safety and Efficacy of Bapineuzumab in Alzheimer Disease Patients

NCT00667810Terminated

Study Evaluating The Efficacy And Safety Of Bapineuzumab In Alzheimer Disease Patients

NCT00916617Terminated

Study Evaluating The Long-Term Safety And Efficacy Of Subcutaneous Bapineuzumab

NCT00996918Terminated

A Long-Term Safety And Tolerability Study Of Bapineuzumab In Alzheimer Disease Patients

NCT00112073Completed

AAB-001 in Patients With Mild to Moderate Alzheimer's Disease

NCT00998764Terminated

A Long-Term Safety And Tolerability Extension Study Of Bapineuzumab In Alzheimer Disease Patients